Preclinical News and Research

RSS

Alnylam first quarter revenues decrease to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2012, and company highlights.

4 May 2012

Study: Breast cancer in young women is enriched with aggressive basal-like tumors

Breast cancer in young women is a biologically unique disease that requires customized management strategies, researchers report at the 4th IMPAKT Breast Cancer Conference, in Brussels, Belgium.

4 May 2012

NCIC CTG, Oncolytics to conduct REOLYSIN Phase II study in colorectal cancer

Oncolytics Biotech Inc. announced today that it has entered into an agreement whereby the NCIC Clinical Trials Group (CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN in patients with advanced or metastatic colorectal cancer.

4 May 2012

Therapy to halt symptoms in Parkinson's patients

Parkinson's disease, a disorder which affects movement and cognition, affects over a million Americans, including actor Michael J. Fox, who first brought it to the attention of many TV-watching Americans. It's characterized by a gradual loss of neurons that produce dopamine. Mutations in the gene known as DJ-1 lead to accelerated loss of dopaminergic neurons and result in the onset of Parkinson's symptoms at a young age.

3 May 2012

Nanoparticle carriers successfully deliver therapeutic doses of cancer drug

Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach. They developed nanoparticle carriers to successfully deliver therapeutic doses of a cancer drug that had previously failed clinical development due to pharmacologic challenges.

3 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

ImmuVen awarded $1.68M NIH Phase II SBIR grant to develop IMV0123

ImmuVen was awarded a Phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease (NIH) for continuing development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus.

2 May 2012

Rigel first quarter net loss increases to $23.2 million

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2012.

2 May 2012

ASNTR honors UTMSH, MSU scientists with 2012 Sanberg awards

At the 19th Annual Conference of the American Society of Neural Therapy and Repair (ASNTR), held April 26 - 28 in Clearwater Beach, Florida, the ASNTR awarded The 2012 Bernard Sanberg Memorial Award for Brain Repair to Timothy J. Collier, PhD, professor of translational science and molecular medicine at Michigan State University and director of the Udall Center of Excellence in Parkinson's Disease Research at Michigan State University and the University of Cincinnati. ASNTR also presented The Molly and Bernard Sanberg Memorial Award to Sean I. Savitz, MD, associat

2 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

CHR-3996 pill shows promise against advanced cancers

Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.

2 May 2012

Vessix V2 Renal Denervation System for hypertension receives CE Mark approval

Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it has received Conformite Europeenne (CE) Mark approval for its V2 Renal Denervation System for the treatment of hypertension.

2 May 2012

Lixte submits IND with FDA to conduct LB-100 Phase I trial for cancer

John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc., announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100.

2 May 2012

Bruker first quarter revenue increases 13.6% to $405.6 million

Bruker Corporation today reported financial results for the first quarter ended March 31, 2012.

2 May 2012

Rexahn obtains additional patent coverage for anti-cancer candidate RX-1792 in Japan

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that the Japanese Patent Office has issued to the Company patent No. 4,934,432, entitled "Quinazoline Derivatives and Therapeutic Use Thereof."

30 Apr 2012

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

Pharmanest commences SHACT Phase I pharmacokinetic study

Karolinska Development: Pharmanest AB today announced that the first patient has been dosed in an open label pharmacokinetic study with its drug candidate SHACT, a product developed for pain relief in connection with intrauterine device (IUD) insertion.

30 Apr 2012

First idiothetic memory study in humans

It's night time. The light suddenly goes out in the room where you are. At the same time you hear somebody crying: "Fire!". You bolt. Will you be able to find your way out in total darkness? Most likely, yes - if the room is somewhat familiar to you and not too big. Escape will be possible because of idiothetic memory, one of two types of human spatial memory. This type of memory relies not on visual information, but on information coming from the body. In the Nencki Institute of Experimental Biology of the Polish Academy of Sciences in Warsaw it was investigated whether this type of memory can be affected by age.

30 Apr 2012

Simulations Plus launches new version of GastroPlus simulation software

Simulations Plus, Inc., a leading provider of simulation and modeling software and consulting services for pharmaceutical discovery and development, announced today the release of Version 8.0 of its flagship GastroPlus simulation software with significantly expanded functionality and user convenience.

27 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012